中文         Site Map |
 
 

1987: We innovated artesunate. The product was authorized Chinese No.1 New Drug by SFDA.
1995: Our API product Bumetanide passed US FDA inspections and obtained API FDA approval.
1998: Our API product Levamisole Hydrochloride passed US FDA inspections and obtained API FDA approval.
2000: Our API product Levamisole Phosphate passed US FDA inspections and obtained API FDA approval.
2002: Our Artesuante tablet was listed on the Essential Drugs of WHO.
2004: Our manufacture site passed SFDA GMP inspection and obtained SFDA GMP Certificate.
2005: Our Artesuanate tablet was pre-qualified by WHO.
2007: Our anti-malarial product Arsuamoon was pre-qualified by WHO.
2008: Our arti-malarial product Arsuamoon passed USP inspection.

 

This site is published by Guilin Pharmaceutical (Shanghai) Corporation,        which is solely responsible for its content. All rights reserved.

© Guilin Pharmaceutical (Shanghai) Co., Ltd. 2017.

网球比分直播雪缘 澳州棒球比分 微信好友麻将下载安装 3d独胆专家预测独胆 葡萄牙与乌拉圭足球比分预测 安徽十一选五 浙20选五基本走势图 山东股票配资 大众麻将手机版赢钱 女皇之心 丹麦对瑞士比分预测 七星彩七星球开奖 二六三股票 赛趣网国标麻将手机版 江苏11选5遗漏 斯诺克比分实时直播 浙江20选5最新开